Cargando…

Molecular Biomarker of Drug Resistance Developed From Patient-Derived Organoids Predicts Survival of Colorectal Cancer Patients

The drug 5-fluorouracil (5-Fu) is the critical composition of colorectal cancer (CRC) treatments. Prognostic and predictive molecular biomarkers for CRC patients (CRCpts) treated with 5-Fu-based chemotherapy can provide assistance for tailoring treatment approach. Here, we established a molecular bi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Lifeng, Tian, Bo, Liu, Wen, Liang, Haitao, You, Yong, Liu, Weizhen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9004628/ https://www.ncbi.nlm.nih.gov/pubmed/35425715 http://dx.doi.org/10.3389/fonc.2022.855674

Ejemplares similares

Patient-Derived Organoids in Precision Medicine: Drug Screening, Organoid-on-a-Chip and Living Organoid Biobank
por: Zhou, Zilong, et al.
Publicado: (2021)

Patient-Derived Organoid Serves as a Platform for Personalized Chemotherapy in Advanced Colorectal Cancer Patients
por: Geevimaan, Khamushavalli, et al.
Publicado: (2022)

Advances of Patient-Derived Organoids in Personalized Radiotherapy
por: Wang, Yuenan, et al.
Publicado: (2022)

Metabolic Heterogeneity in Patient Tumor-Derived Organoids by Primary Site and Drug Treatment
por: Sharick, Joe T., et al.
Publicado: (2020)

Imaging-Based Machine Learning Analysis of Patient-Derived Tumor Organoid Drug Response
por: Spiller, Erin R., et al.
Publicado: (2021)

Patient-derived xenografts or organoids in the discovery of traditional and self-assembled drug for tumor immunotherapy
por: Zhang, Wei, et al.
Publicado: (2023)

Standardizing Patient-Derived Organoid Generation Workflow to Avoid Microbial Contamination From Colorectal Cancer Tissues
por: Marinucci, Mattia, et al.
Publicado: (2022)

Patient-Derived Cancer Organoids as Predictors of Treatment Response
por: Verduin, Maikel, et al.
Publicado: (2021)

Patient-Derived Tumor Organoids: New Progress and Opportunities to Facilitate Precision Cancer Immunotherapy
por: Wang, Ji, et al.
Publicado: (2022)

Patient-Derived Nasopharyngeal Cancer Organoids for Disease Modeling and Radiation Dose Optimization
por: Lucky, Sasidharan Swarnalatha, et al.
Publicado: (2021)

Patient-derived rectal cancer organoids—applications in basic and translational cancer research
por: Yan, Yumeng, et al.
Publicado: (2022)

Fatty Acid Metabolism-Related lncRNAs Are Potential Biomarkers for Predicting the Overall Survival of Patients With Colorectal Cancer
por: Peng, Yurui, et al.
Publicado: (2021)

Organoid: Next-Generation Modeling of Cancer Research and Drug Development
por: Liu, Jungang, et al.
Publicado: (2022)

Corrigendum: Fatty Acid Metabolism-Related lncRNAs Are Potential Biomarkers for Predicting the Overall Survival of Patients With Colorectal Cancer
por: Peng, Yurui, et al.
Publicado: (2022)

Screening of an individualized treatment strategy for an advanced gallbladder cancer using patient-derived tumor xenograft and organoid models
por: Tan, Dengxu, et al.
Publicado: (2022)

Organoids and metastatic orthotopic mouse model for mismatch repair-deficient colorectal cancer
por: Song, Yurong, et al.
Publicado: (2023)

Patient-derived organoids as a platform for drug screening in metastatic colorectal cancer
por: He, Xingfeng, et al.
Publicado: (2023)

A deep learning model for drug screening and evaluation in bladder cancer organoids
por: Zhang, Shudi, et al.
Publicado: (2023)

Global cluster analysis and network visualization in organoids in cancer research: a scientometric mapping from 1991 to 2021
por: Tan, Shunshun, et al.
Publicado: (2023)

Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening
por: Verissimo, Carla S, et al.
Publicado: (2016)

“Proteotranscriptomic analysis of advanced colorectal cancer patient derived organoids for drug sensitivity prediction”
por: Papaccio, Federica, et al.
Publicado: (2023)

Patient-Derived Organoid Facilitating Personalized Medicine in Gastrointestinal Stromal Tumor With Liver Metastasis: A Case Report
por: Cao, Ying, et al.
Publicado: (2022)

Patient‐derived organoids for personalized gallbladder cancer modelling and drug screening
por: Yuan, Bo, et al.
Publicado: (2022)

Association of CT-Based Delta Radiomics Biomarker With Progression-Free Survival in Patients With Colorectal Liver Metastases Undergo Chemotherapy
por: Ye, Shuai, et al.
Publicado: (2022)

Derivation and Clinical Validation of a Redox-Driven Prognostic Signature for Colorectal Cancer
por: Dang, Qin, et al.
Publicado: (2021)

Serum Chemokine CXCL7 as a Diagnostic Biomarker for Colorectal Cancer
por: Li, Longhai, et al.
Publicado: (2019)

Opportunities and challenges of hepatocellular carcinoma organoids for targeted drugs sensitivity screening
por: Xie, Cuiying, et al.
Publicado: (2023)

Organoids from patient biopsy samples can predict the response of BC patients to neoadjuvant chemotherapy
por: Shu, Dan, et al.
Publicado: (2022)

The effect of metabolic syndrome on postoperative complications and long-term survival of patients with colorectal cancer
por: Zhu, Ce, et al.
Publicado: (2023)

Patient-derived organoids facilitating individual therapy in an adolescent with embryonal rhabdomyosarcoma of the cervix: a case report and literature review
por: Qiao, Xinyu, et al.
Publicado: (2023)

Young-Onset Early Colorectal Cancer Had Similar Relative Survival to but Better Overall Survival Than Conventional Early Colorectal Cancer: A Large Population-Based Study
por: Chen, Jin-Nan, et al.
Publicado: (2020)

Corrigendum: Association of CT-based delta radiomics biomarker with progression-free survival in patients with colorectal liver metastases undergo chemotherapy
por: Ye, Shuai, et al.
Publicado: (2023)

Raltitrexed as a synergistic hyperthermia chemotherapy drug screened in patient-derived colorectal cancer organoids
por: Zeng, Lisi, et al.
Publicado: (2021)

Cutoff value of IC(50) for drug sensitivity in patient-derived tumor organoids in colorectal cancer
por: Tang, Yuting, et al.
Publicado: (2023)

Patient‐derived organoids as a preclinical platform for precision medicine in colorectal cancer
por: Cho, Young‐Won, et al.
Publicado: (2022)

Exosome-Derived Long Non-Coding RNAs as Non-Invasive Biomarkers of Bladder Cancer
por: Su, Quanxin, et al.
Publicado: (2021)

Plasma Exosome-Derived Sentrin SUMO-Specific Protease 1: A Prognostic Biomarker in Patients With Osteosarcoma
por: Wang, Li, et al.
Publicado: (2021)

Patient Derived Organoids Confirm That PI3K/AKT Signalling Is an Escape Pathway for Radioresistance and a Target for Therapy in Rectal Cancer
por: Wanigasooriya, Kasun, et al.
Publicado: (2022)

Drug Discovery via Human-Derived Stem Cell Organoids
por: Liu, Fangkun, et al.
Publicado: (2016)

Establishment of Organoids From Human Epithelioid Sarcoma With the Air-Liquid Interface Organoid Cultures
por: Wakamatsu, Toru, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_g01kri347t3tjrm0i9cdo63na7